HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Clinical briefs for Thursday, March 18
By
Alicia Lasek
Mar 18, 2021
Feds invest $255 million more in COVID tests for long-term care, but some say vaccines, funding are more urgent needs … PharmaCorr spin-off to expand post-acute, LTC services … FDA approves Melinta’s...
Most COVID-19 antibody treatments given in assisted living, analysts find
By
Alicia Lasek
Feb 22, 2021
Fully 67% of monoclonal antibody treatments have been administered in assisted living communities. Health officials would like to encourage greater use.
Feds authorize combo antibody infusion to treat COVID-19 in older adults with chronic disease
By
Alicia Lasek
Feb 11, 2021
The latest Eli Lilly therapy has received emergency approval for treating mild to moderate COVID-19 in patients at high risk for progressing to severe disease and/or hospitalization. This includes adults...
New ‘weapon in our arsenal’: Antibody drug cuts COVID risk by 80 percent in LTC residents
By
Alicia Lasek
Jan 22, 2021
Staff and residents who received Eli Lilly’s monoclonal antibody therapy were less likely to contract symptomatic COVID-19 than placebo groups in a late-stage trial. Industry advocates are hailing...
Clinical briefs for Friday, Dec. 4
By
Alicia Lasek
Dec 03, 2020
CVS Health partners with feds to administer COVID-19 antibody therapy at LTC facilities … Three former U.S. presidents to take coronavirus vaccine on camera, reassure public … Select Rehab becomes...
Dosing discrepancy for Eli Lilly’s new COVID therapy begets clinician confusion
By
Alicia Lasek
Nov 12, 2020
Some clinicians are questioning the decision to authorize 700 mg doses of the intravenous drug rather than a higher dose that was effective in clinical trials. But Eli Lilly and federal health officials...
AMDA to feds: Delay antibody treatment in nursing homes, engage LTC medical directors
By
Alicia Lasek
Nov 09, 2020
“This is the right therapy, but it needs more study … and it needs engaged medical director oversight and supervision,” says AMDA’s Executive Director Chris Laxton. Emergency approval of COVID...
Clinical Briefs for Friday, June 12
By
Alicia Lasek
Jun 11, 2020
Population-wide facemask use dramatically cuts COVID-19 transmission rates, finds study … Antibody COVID-19 treatment could be authorized by September … Treatment target has potential for chronic kidney...